scholarly journals Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes

2018 ◽  
Vol 19 (8) ◽  
pp. 2211 ◽  
Author(s):  
Josiah Ochieng ◽  
Gladys Nangami ◽  
Amos Sakwe ◽  
Cierra Moye ◽  
Joel Alvarez ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Tumor Progression ◽  
Tumor Cells ◽  
Protein Product ◽  
High Serum ◽  
Ectopic Calcification ◽  
Fetuin A ◽  
Multifunctional Protein ◽  
Pathophysiological Role

Fetuin-A is the protein product of the AHSG gene in humans. It is mainly synthesized by the liver in adult humans and is secreted into the blood where its concentration can vary from a low of ~0.2 mg/mL to a high of ~0.8 mg/mL. Presently, it is considered to be a multifunctional protein that plays important roles in diabetes, kidney disease, and cancer, as well as in inhibition of ectopic calcification. In this review we have focused on work that has been done regarding its potential role(s) in tumor progression and sequelae of diabetes. Recently a number of laboratories have demonstrated that a subset of tumor cells such as pancreatic, prostate and glioblastoma multiform synthesize ectopic fetuin-A, which drives their progression. Fetuin-A that is synthesized, modified, and secreted by tumor cells may be more relevant in understanding the pathophysiological role of this enigmatic protein in tumors, as opposed to the relatively high serum concentrations of the liver derived protein. Lastly, auto-antibodies to fetuin-A frequently appear in the sera of tumor patients that could be useful as biomarkers for early diagnosis. In diabetes, solid experimental evidence shows that fetuin-A binds the β-subunit of the insulin receptor to attenuate insulin signaling, thereby contributing to insulin resistance in type 2 diabetes mellitus (T2DM). Fetuin-A also may, together with free fatty acids, induce apoptotic signals in the beta islets cells of the pancreas, reducing the secretion of insulin and further exacerbating T2DM.

scholarly journals Fetuin-A as a Marker of NAFLD

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A413-A414
Author(s):  
Mala Dharmalingam ◽  
Ganavi Pattabhi
Keyword(s):  
Type 2 Diabetes ◽  
Transient Elastography ◽  
High Serum ◽  
Diabetic Patients ◽  
Fasting Insulin ◽  
Type 2 Diabetic Patients ◽  
Fetuin A ◽  
Nonalcoholic Fatty Liver ◽  
Reliable Marker

Abstract Fetuin-A has been implicated in the causation of metabolic disorders such as obesity, diabetes, and hepatic steatosis. There are numerous studies which have shown the association between levels of fetuin-A in Type 2 diabetes mellitus (T2DM) and Nonalcoholic fatty liver disease (NAFLD). The levels of fetuin-A in newly detected type 2 diabetic patients (NDD) and its correlation with presence of NAFLD has not been studied. Objective: To study the fetuin-A levels in patients with NDD and its correlation with NAFLD. Methods: A total of 60 newly diagnosed type 2 diabetes (NDD) were studied. Diagnosis of NAFLD was made on the basis of transient elastography. Serum fetuin-A and serum fasting insulin were measured along with other investigations. Results: Percentage of patients with NAFLD in NDD was 53.33%. Fetuin-A levels were significantly higher in NDD with NAFLD compared to those without NAFLD. There was no association of fetuin-A with age, both systolic and diastolic blood pressure, FBS, HbA1c, fasting insulin, HOMA-IR, QUICKI and markers of advanced fibrosis. Fetuin-A levels beyond 1166.5 mcg/ml could predict the development of NAFLD with OR of 4.33 (95%CI:1.364–13.77) which remained significant after adjustment for various confounding factors. Conclusion: Fetuin-A is a reliable marker of NAFLD in NDD and is positively associated with IR. The observation in this study suggests that high serum fetuin-A levels in patients with NAFLD do not merely reflect the effects of insulin resistance, but also a more extensive distortion of liver architecture.

High serum miRNA 550a-5p levels are risk factors for incident fractures in older postmenopausal women with type 2 diabetes

2016 ◽  
Author(s):  
Ursula Heilmeier ◽  
Matthias Hackl ◽  
Susanna Skalicky ◽  
Sylvia Weilner ◽  
Fabian Schroeder ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Postmenopausal Women ◽  
High Serum ◽  
Serum Mirna

scholarly journals Association between alcohol consumption and plasma fetuin-A and its contribution to incident type 2 diabetes in women

Diabetologia ◽  
2013 ◽  
Vol 57 (1) ◽  
pp. 93-101 ◽  
Author(s):  
Sylvia H. Ley ◽  
Qi Sun ◽  
Monik C. Jimenez ◽  
Kathryn M. Rexrode ◽  
JoAnn E. Manson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Alcohol Consumption ◽  
Fetuin A ◽  
Incident Type ◽  
Incident Type 2 Diabetes

Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus

Metabolism ◽  
2010 ◽  
Vol 59 (6) ◽  
pp. 873-878 ◽  
Author(s):  
Masanori Emoto ◽  
Katsuhito Mori ◽  
Eiko Lee ◽  
Naoya Kawano ◽  
Yuko Yamazaki ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fetuin A ◽  
Calcified Plaque

Serum fetuin-A levels in obese and non-obese subjects with and without type 2 diabetes mellitus

2018 ◽  
Vol 476 ◽  
pp. 98-102 ◽  
Author(s):  
Zhong-wei Zhou ◽  
Hui-xiang Ju ◽  
Ming-zhong Sun ◽  
Hong-mei Chen ◽  
Qing-ping Fu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fetuin A ◽  
Obese Subjects

scholarly journals Elabela levels in patients with type 2 diabetes: can it be a marker for diabetic nephropathy?

2020 ◽  
Vol 20 (2) ◽  
pp. 833-840
Author(s):  
Erhan Onalan ◽  
Yusuf Doğan ◽  
Ebru Onalan ◽  
Nevzat Gozel ◽  
Ilay Buran ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
High Serum ◽  
Control Group ◽  
Diabetic Patients ◽  
Healthy Individuals ◽  
Urine Albumin ◽  
Healthy Control ◽  
Group 2

Backround: Elabela (ELA) is a hormone that is secreted at high levels in the kidneys of a healthy adult. This study aims to investigate whether serum ELA levels of patients with Type 2 Diabetes vary with the severity of renal damage. Methods: Our study included 50 healthy control subjects and 100 diabetic patients, who were categorized into groups based on urine albumin/creatinine ratios (ACR). Patients included in the study were assigned to four groups: Group 1 (healthy control), Group 2 (ACR<29mg/g), Group 3 (ACR=30-299 mg/g), and Group 4 (ACR>300 mg/g normal or high serum creatinine). Physical examination findings, demographic characteristics of the study group were recorded, and serum ELA levels and other laboratory parameters were assessed using appropriate methods. Results: The results of the study indicated that ELA levels determined in healthy individuals gradually decreased through stages of normal albuminuria, microalbuminuria, and macroalbuminuria. Moreover, ELA had a significant negative corre- lation with LDL-C (r=-0.201, p=0.014), glucose (r=-0.437, P<0.001), retinopathy (r=-0.222, P=0.006), serum BUN (r=- 0.161, P=0.049), and a positive correlation with eGFR (r=0.250, P=0.002). Conclusions: The fact that ELA levels are higher in healthy individuals compared to diabetic patients without microalbu- minuria, and higher in diabetic patients without microalbuminuria compared to patients with advanced albuminuria and kidney damage, suggests that the ELA level can be an important clinical prognostic variable and even a promising agent for the treatment of diabetic nephropathy patients. Keywords: Elabela, diabetes, diabetic kidney disease, albuminuria.

scholarly journals Insulin-Sensitizing Therapy Attenuates Type 2 Diabetes-Mediated Mammary Tumor Progression

Diabetes ◽  
2009 ◽  
Vol 59 (3) ◽  
pp. 686-693 ◽  
Author(s):  
Y. Fierz ◽  
R. Novosyadlyy ◽  
A. Vijayakumar ◽  
S. Yakar ◽  
D. LeRoith
Keyword(s):  
Type 2 Diabetes ◽  
Tumor Progression ◽  
Mammary Tumor ◽  
Mammary Tumor Progression
Sign in / Sign up

Export Citation Format

Share Document